

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

Cell Signaling Technology

RRID:SCR_002071

Type: Tool

Proper Citation

Cell Signaling Technology (RRID:SCR_002071)

Resource Information

URL: <http://www.cellsignal.com/>

Proper Citation: Cell Signaling Technology (RRID:SCR_002071)

Description: Privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study cell signaling pathways that impact human health.

Abbreviations: CST

Resource Type: commercial organization

Keywords: antibodies, ELISA kits, ChIP kits, proteomic kits, cell signaling pathways

Resource Name: Cell Signaling Technology

Resource ID: SCR_002071

Alternate IDs: ISNI: 0000 0004 0580 0138, nlx_152330, Wikidata: Q3392342, SCR_004431, grid.420530.0, nif-0000-20826

Alternate URLs: <https://ror.org/03k4zc121>

Record Creation Time: 20220129T080211+0000

Record Last Update: 20260808T185737+0000

Ratings and Alerts

No rating or validation information has been found for Cell Signaling Technology.

No alerts have been found for Cell Signaling Technology.

Data and Source Information

Usage and Citation Metrics

We found 12353 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Martin A, et al. (2026) Generalizable, high-throughput image analysis of subcellular structures using dispersion indices. *iScience*, 29(4), 115371.

Li C, et al. (2026) ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing. *bioRxiv* : the preprint server for biology.

Ziegler Y, et al. (2026) JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6. *NPJ breast cancer*, 12(1).

Demuro S, et al. (2026) A Polypharmacology-Driven Approach to Alzheimer's Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3 β /FYN- γ /DYRK1A) Inhibitors. *Journal of medicinal chemistry*, 69(9), 9991.

Scholes NS, et al. (2026) Inhibitors supercharge kinase turnover through native proteolytic circuits. *Nature*, 649(8098), 1032.

Stolarik E, et al. (2026) Inhibition of cell surface GRP78 on brain tumors reverses drug resistance and stops cancer stem cell expansion. *The Journal of biological chemistry*, 111146.

Moine L, et al. (2026) Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST. *Journal of medicinal chemistry*, 69(8), 9083.

Jiang T, et al. (2026) Blood-brain barrier disruption and neuroinflammation in the hippocampus of a cardiac arrest porcine model: Single-cell RNA sequencing analysis. *Neural regeneration research*, 21(2), 742.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Noorani I, et al. (2025) Extrachromosomal DNA-Driven Oncogene Spatial Heterogeneity and Evolution in Glioblastoma. *Cancer discovery*, 15(10), 2078.

Bird SG, et al. (2025) Regulatory Role for Tumor Suppressor REST on Estrogen Receptor (ESR1) Expression and Leiomyoma Pathophysiology. *bioRxiv* : the preprint server for biology.

Thompson AD, et al. (2025) 5-Hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute

kidney injury in mice. American journal of physiology. Renal physiology, 329(6), F834.

Bird SG, et al. (2025) Regulatory role for tumor suppressor REST on estrogen receptor (ESR1) expression and leiomyoma pathophysiology. The Journal of biological chemistry, 302(1), 111017.

Cluzet V, et al. (2025) Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways. Molecular cancer therapeutics, 24(8), 1197.

Tsimberidou AM, et al. (2025) Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6), 965.

Lafargue A, et al. (2025) Twist1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of Twist1. Neoplasia (New York, N.Y.), 66, 101179.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Molecular cancer therapeutics, 24(6), 843.

Li C, et al. (2025) The NADC30-like PRRSV activates the integrin α V subunit to facilitate its entry into Marc-145 cells. PloS one, 20(3), e0316239.

Wang X, et al. (2025) Artesunate enhances the efficacy of enzalutamide in advanced prostate cancer. The Journal of biological chemistry, 301(5), 108458.

Zelkoski AE, et al. (2025) Ionizable lipid nanoparticles of mRNA vaccines elicit NF- κ B and IRF responses through toll-like receptor 4. NPJ vaccines, 10(1), 73.